Sign in
Not yet recruitingPhase 4

Normal Saline Versus Ringer's Lactate for Initial Fluid Resuscitation in Sepsis

Key facts

Who runs it
Egemen Yildiz
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
88 people, planned
Started
Nov 2025
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ringer's Lactate
  • Normal Saline (0.9% Sodium Chloride)
Record updated
21 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Adult male or female patients (≥18 years of age) presenting to the emergency department
  • Diagnosed or suspected sepsis secondary to an infectious cause
  • Provision of written informed consent by the patient, or if the patient is unable to consent, by a first-degree relative or legally authorized representative

Who cannot take part

  • Patients who are receiving cardiopulmonary resuscitation (CPR) or who require endotracheal intubation at the time of presentation
  • Cases in which the treating physician anticipates that fluid therapy might be delayed due to study participation
  • Patients with severe volume depletion unrelated to sepsis (e.g., diabetic ketoacidosis, burns, or active gastrointestinal bleeding)
  • Patients with hypotension that is not related to sepsis (e.g., active hemorrhage or intracranial bleeding)
  • Patients with clinical signs of pulmonary edema or congestive heart failure
  • Cases in which the treating physician determines that one isotonic crystalloid (Ringer's lactate or 0.9% NaCl) is clearly superior to the other due to clinical condition or comorbidities
  • Severe renal failure with oliguria or anuria
  • Decompensated heart failure
  • Conditions associated with impaired lactate metabolism, such as lactic acidosis, severe liver failure, and cirrhosis with ascites
  • Patients with severe hyperkalemia (serum potassium level of at least 6.5 mmol/L with ECG changes)
  • Known hypersensitivity to sodium lactate
  • Age under 18 years old
  • Pregnant women
  • Informed consent was not obtained from the patient or their first-degree relative/legal guardian
  • Patients requiring immediate hospital or ICU admission before completion of initial emergency department resuscitation
  • Patients with sepsis sources requiring urgent invasive intervention known to directly affect mortality (e.g., an undrainable abscess or osteomyelitis); Additional exclusion criteria based on the contraindications listed in the Ringer's lactate product information:,
  • Extracellular hyperhydration or hypervolemia
  • Hypercalcemia
  • Metabolic alkalosis or severe metabolic acidosis
  • Current use of digitalis preparations (e.g., digoxin)

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Sepsis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aims to determine if the type of intravenous fluid used for initial resuscitation affects the short-term outcomes of adult patients with sepsis who are treated in the emergency department.

Read full original descriptionShow less

The main questions it aims to answer are:

Does using Ringer's lactate instead of 0.9% sodium chloride (normal saline) reduce 24-hour mortality in patients with sepsis?

Does the type of fluid influence other short-term outcomes, such as the need for vasopressors, mechanical ventilation, hemodialysis, and length of hospital stay?

Researchers will compare two groups of participants:

* The Ringer's lactate group (intervention group) * The 0.9% sodium chloride group (control group).

Participants will:

* Receive either Ringer's lactate or normal saline for initial fluid resuscitation as part of standard sepsis care. * They will be observed for 24 hours to assess survival and other early outcomes.

The 2 groups in the trial

  • Ringer's Lactate GroupTreatment being tested

    Eligible participants in this group will receive Ringer's lactate solution as the initial intravenous fluid for resuscitating sepsis. This will be administered through a peripheral intravenous line at a rate of 1000 ml over 30-60 minutes, as determined by the attending physician and the patient's clinical condition. All other treatments will follow standard sepsis care protocols.

    Treatment: Ringer's Lactate

  • Normal Saline GroupExisting treatment, for comparison

    Eligible participants in this arm will receive 0.9% sodium chloride (normal saline) as the initial intravenous fluid for resuscitation in sepsis. This will be administered through a peripheral intravenous line at a rate of 1000 ml over 30-60 minutes, as determined by the attending physician and the patient's clinical condition. All other treatments will follow standard sepsis care protocols.

    Treatment: Normal Saline (0.9% Sodium Chloride)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-Center, Randomized Controlled Trial Comparing Normal Saline and Ringer's Lactate for Initial Fluid Resuscitation in Adult Patients With Sepsis in the Emergency Department
Criteria questions
Built from NCT07240701, who can take part
Record updated
21 November 2025